RT Journal Article
T1 Managing the patient undergoing transcatheter aortic valve replacement with ongoing mitral regurgitation
A1 Tirado-Conte, Gabriela
A1 McInerney, Angela
A1 Jimenez-Quevedo, Pilar
A1 Carnero, Manuel
A1 Marroquin Donday, Luis A
A1 Agustin, Alberto De
A1 Witberg, Guy
A1 Pozo, Eduardo
A1 Islas, Fabian
A1 Marcos-Alberca, Pedro
A1 Cobiella, Javier
A1 Koronowski, Ran
A1 Macaya Miguel, Carlos
A1 Rodes-Cabau, Josep
A1 Nombela-Franco, Luis
AB AbstractIntroduction: Significant mitral regurgitation (MR) frequently coexists in patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). These patients have worse clinical outcomes than those with non-significant MR, especially if MR persists after treatment of the aortic stenosis. The optimal treatment approach for this challenging high-risk population is not well defined.Areas covered: This review aims to present the current literature on concomitant significant MR in the TAVR population, and to provide a comprehensive algorithmic approach for clinical decision-making in this challenging cohort of patients.Expert opinion: Concomitant mitral and aortic valve disease is a complex clinical entity. An exhaustive and comprehensive assessment of patient's clinical characteristics and mitral valve anatomy and function is required in order to assess the surgical risk, predict the MR response after AVR and evaluate the feasibility of percutaneous MV treatment if necessary. Further developments in transcatheter techniques will expand the indications for double valve treatment in operable and inoperable patients with concomitant significant MR and aortic stenosis.
PB Taylor Francis
YR 2021
FD 2021-07-30
LK https://hdl.handle.net/20.500.14352/133956
UL https://hdl.handle.net/20.500.14352/133956
LA eng
NO Tirado-Conte G, McInerney A, Jimenez-Quevedo P, Carnero M, Marroquin Donday LA, De Agustin A, et al. Managing the patient undergoing transcatheter aortic valve replacement with ongoing mitral regurgitation. Expert Review of Cardiovascular Therapy 2021;19:711–23. https://doi.org/10.1080/14779072.2021.1955347.
DS Docta Complutense
RD 22 mar 2026